Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Melanotan I

Afamelanotide Precursor / Linear MSH Analog

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Two evidence tiers must be kept apart. The gray-market injectable sold as 'Melanotan 1' for cosmetic tanning, which is what this entry markets, is unapproved and illegal to supply in the UK, Australia, and the EU, rests on no controlled human tanning trials, and is associated in published case reports with darkening and eruption of moles, dysplastic (atypical) nevi, and melanoma, so that use grades grade 1. The SAME molecule, purified and formulated as the implant Scenesse (afamelanotide), is a different tier: two multicenter placebo-controlled Phase 3 RCTs (Langendonk et al., NEJM 2015; EU n=74, US n=94) supported longer pain-free light exposure in erythropoietic protoporphyria, earning EMA approval in 2014 and FDA approval in October 2019, which would grade grade 4 for that specific approved indication only. The entry's grade 3 is graded here against its actual subject, the cosmetic tanning use, and corrected down to 1.

FDA
Same molecule is FDA approved as Scenesse (afamelanotide) since Oct 2019 for erythropoietic protoporphyria; the gray-market injectable sold as 'Melanotan 1' for tanning is unapproved and not legally marketed for that use
WADA
Not specifically named on the WADA Prohibited List; the unapproved gray-market form falls under S2 non-approved peptide hormones/analogs and should be treated as prohibited by athletes

Reference only. Not medical advice.

What can go wrong

Gray-market tanning use is unapproved and illegal to supply in the UK/EU/Australia; associated in case reports with mole darkening, eruptive and dysplastic nevi, and melanoma, and carries contamination/sterility risk from underground supply.

Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Melanotan I. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

The linear alpha-MSH analog [Nle4-D-Phe7]-alpha-MSH, which is the same molecule that Clinuvel developed into the FDA- and EMA-approved implant Scenesse (afamelanotide) for erythropoietic protoporphyria. The version sold on the gray market as 'Melanotan 1' for cosmetic tanning is unapproved, illegal to supply in the UK, EU, and Australia, and is associated in case reports with mole changes and melanoma.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Tanning (without UV)
  • Photoprotection

How it is supposed to work

Melanotan I is a melanocortin peptide that stimulates the skin’s pigment cells through the MC1R receptor to produce more melanin, creating a tan with less ultraviolet exposure. Unlike its non-selective sibling Melanotan II, it is more focused on pigmentation and does not meaningfully drive the libido and appetite effects, which makes it the cleaner of the two tanning peptides. Its regulated, approved relative is afamelanotide.

Melanotan I, also called afamelanotide, is a linear 13-amino-acid analog of the natural hormone alpha-MSH, selective for the melanocortin-1 receptor on pigment cells. This is the same molecule covered in this library’s afamelanotide entry, viewed here through the lens of its gray-market tanning use and its comparison with Melanotan II.

Type
Alpha-MSH analog
Length
13 amino acids
Target
MC1R, selective
Approved as
Afamelanotide, for EPP
Tanning use
Unapproved, needs UV
Vs MT-2
Cleaner, selective

The Approved Tanning Molecule, Sold Gray-Market For An Unapproved Use

Melanotan I is unusual in this library because the very same molecule both achieved full pharmaceutical approval and is sold underground, and the honest framing lives in that gap. As the approved drug afamelanotide, sold as Scenesse, it is a controlled-release implant approved by the FDA in 2019 and the European regulator in 2014 for erythropoietic protoporphyria, a rare disorder causing severe pain on light exposure. It earned that approval because it does more than darken skin: by selectively activating the melanocortin-1 receptor it shifts pigment toward UV-absorbing eumelanin and upregulates DNA repair, cutting sunburn-cell formation by roughly half, which is real photoprotection. Compared with Melanotan II, it is the cleaner, lower-risk option, skin-focused and selective, without Melanotan II’s sexual, nausea, and more dangerous effects, and backed by rigorous trials and long-term safety data. The honest distinction is critical. The approved product is an implant for a rare disease, prescribed and monitored, not an injectable tanning aid. The Melanotan I sold for cosmetic tanning is the same molecule as an unregulated injectable powder used off-label, from gray-market suppliers whose purity is measurably lower than pharmaceutical grade. Even this safer tanning peptide still needs UV exposure to produce a visible tan, and because it stimulates pigment cells it warrants dermatological mole-monitoring, with extra caution for anyone with a melanoma history, though approved-trial data has not shown increased melanoma.

Safety in detail

The regulated drug Scenesse and the gray-market tanning product are the same molecule but not the same thing; the tanning form is sourced without purity, dose, or sterility controls and its melanocyte activation is associated with atypical nevi and melanoma in published reports.

  • More MC1R-selective than Melanotan II, so it largely avoids the priapism and strong nausea associated with the non-selective peptide.
  • It still darkens moles, which can complicate skin-cancer detection, and the melanoma question that shadows tanning peptides applies.
  • Gray-market product is unregulated, with the usual identity and purity risks.
  • Not approved for cosmetic tanning; the approved melanocortin option is afamelanotide for a specific medical condition.

Children and teenagers

Melanotan I has no cosmetic pediatric use; the approved afamelanotide implant is used only for its rare-disease indication under specialist care, and gray-market tanning use is inappropriate for minors.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Melanotan I has two distinct economies. As afamelanotide it is a prescription orphan drug for a rare disease, manufactured and sold under regulatory oversight. As gray-market Melanotan I it is an injectable research-grade powder sold for cosmetic tanning, an unapproved use, through unregulated suppliers, where purity and sourcing are real concerns.

How we got here

The linear alpha-MSH analog [Nle4-D-Phe7]-alpha-MSH was synthesized in the University of Arizona program led by Victor Hruby and Mac Hadley in the 1980s as a more potent, more stable melanocortin agonist, and the tanning-focused public nickname 'Melanotan' dates from that era. One and the same molecule then split into two products with opposite regulatory fates. Clinuvel Pharmaceuticals developed it under the codes CUV1647 and later the name afamelanotide, running the Phase 3 EPP trials that led to EMA approval in 2014 and FDA approval of the Scenesse implant in October 2019. In parallel, an unlicensed injectable and nasal-spray version sold as 'Melanotan 1' spread through the cosmetic-tanning gray market, where it remains illegal to supply in the UK, Australia, and the EU and is distinct from Melanotan II, which is the separate cyclic analog associated with priapism and stronger appetite and libido effects.

Melanotan I was developed at the University of Arizona in the 1980s and 1990s alongside Melanotan II, but took the more selective path. Refined into afamelanotide and developed by Clinuvel, it earned European approval in 2014 and FDA approval in 2019, as the Scenesse implant, for erythropoietic protoporphyria, while the same molecule continued to be sold gray-market for cosmetic tanning.

The numbers behind the grade

Type
Melanocortin (MC1R) peptide
Effect
Tanning
Vs MT-II
More selective, fewer effects
Approved relative
Afamelanotide
Approved (cosmetic)
No
Status
Gray-market

The people taking it

The cleaner, more pigment-selective cousin of the notorious Melanotan II, less famous and less risky, but still an unapproved gray-market tanning peptide.

Melanotan I’s legitimate users are patients with erythropoietic protoporphyria treated with the approved implant. Its gray-market users are cosmetic tanners who choose it as the cleaner, more selective alternative to Melanotan II.

Used gray-market for cosmetic tanning with fewer systemic effects than Melanotan II; not approved for that use. Its selective, approved relative afamelanotide is used only for a rare medical condition.

Set against the alternatives

Melanotan I is one of the melanocortin peptides, the same molecule as this library’s afamelanotide entry, the safer and more selective sibling of Melanotan II, and a relative of the sexual-function peptide PT-141 and the parent hormone alpha-MSH. Its defining contrast is with Melanotan II: selective and skin-focused versus broad and systemic, approved as a real drug versus never approved, gradual and cleaner versus faster but riskier. Among tanning peptides it is the lower-risk choice, and the only one whose molecule reached genuine approval.

What we do not know

  • Whether selective MC1R tanning is meaningfully safer over the long term.
  • How the mole-darkening and melanoma questions apply to Melanotan I specifically.
  • Whether any cosmetic melanocortin tanning product could be developed responsibly.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Sold only as gray-market research material for tanning, which is not an approved use. It is safer than Melanotan II but still unregulated and unstudied as a product; the mole-darkening and melanoma cautions apply, and dermatologic oversight is advisable for anyone who uses it.

Sold gray-market as research material, mostly synthesized overseas, with no quality assurance; the approved relative afamelanotide comes only through regulated medical channels.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Melanotan I.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Afamelanotide development2000s-2010s

    The closely related, selective melanocortin peptide afamelanotide was developed and approved (as an implant) for a rare light-sensitivity disorder, validating the tanning mechanism in a controlled form.

  • Photoprotection research2000s

    Melanocortin tanning peptides were studied for inducing protective pigmentation, the original rationale.

  • Melanotan I human efficacylimited

    As a gray-market product, Melanotan I itself lacks the trial base of its approved relative; the evidence rides largely on afamelanotide and the shared mechanism.